A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

January 28, 2028

Study Completion Date

January 28, 2028

Conditions
Advanced Solid TumorsMalignant Neoplasm
Interventions
BIOLOGICAL

MK-3120

IV infusion

Trial Locations (38)

704

RECRUITING

National Cheng Kung University Hospital ( Site 0161), Tainan City

6230

RECRUITING

Hacettepe Universite Hastaneleri ( Site 0130), Ankara

10002

RECRUITING

National Taiwan University Hospital ( Site 0160), Taipei

23219

RECRUITING

Virginia Commonwealth University ( Site 1008), Richmond

28040

RECRUITING

Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111), Madrid

29016

RECRUITING

Hospital Universitario Virgen de la Victoria ( Site 0114), Málaga

33136

RECRUITING

University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003), Miami

34010

RECRUITING

Koc University, School of Medicine ( Site 0133), Istanbul

35000

RECRUITING

Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054), Rennes

35249

RECRUITING

The University of Alabama at Birmingham ( Site 1005), Birmingham

59000

RECRUITING

Centre Oscar Lambret ( Site 0051), Lille

71004

RECRUITING

Chi Mei Medical Center ( Site 0162), Tainan City

100034

RECRUITING

Peking University First Hospital ( Site 0180), Beijing

130021

RECRUITING

The First Hospital of Jilin University ( Site 0185), Changchun

400030

RECRUITING

Chongqing Cancer Hospital ( Site 0186), Chongqing

610041

RECRUITING

West China Hospital Sichuan University ( Site 0187), Chengdu

3109601

RECRUITING

Rambam Health Care Campus ( Site 0082), Haifa

4941492

RECRUITING

Rabin Medical Center ( Site 0081), Petah Tikva

5265601

RECRUITING

Sheba Medical Center ( Site 0080), Ramat Gan

7500653

RECRUITING

Centro de Estudios Clínicos SAGA ( Site 0033), Santiago

7500921

RECRUITING

FALP ( Site 0031), Santiago

8330032

RECRUITING

Pontificia Universidad Catolica de Chile ( Site 0032), Santiago

8420383

RECRUITING

Bradford Hill Centro de Investigaciones Clinicas ( Site 0030), Santiago

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009), Hackensack

135-8550

RECRUITING

Cancer Institute Hospital of JFCR ( Site 0192), Koto

541-8567

RECRUITING

Osaka International Cancer Institute ( Site 0191), Osaka

6525 GA

RECRUITING

Radboudumc ( Site 0091), Nijmegen

1066 CX

RECRUITING

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090), Amsterdam

1081HV

RECRUITING

Amsterdam UMC, locatie VUmc ( Site 0093), Amsterdam

3015 GD

RECRUITING

Erasmus Medisch Centrum ( Site 0092), Rotterdam

03080

RECRUITING

Seoul National University Hospital ( Site 0150), Seoul

03722

RECRUITING

Severance Hospital Yonsei University Health System ( Site 0151), Seoul

05505

RECRUITING

Asan Medical Center ( Site 0153), Seoul

06351

RECRUITING

Samsung Medical Center ( Site 0152), Seoul

08908

RECRUITING

Institut Català d'Oncologia - L'Hospitalet ( Site 0113), L'Hospitalet de Llobregat

08036

RECRUITING

HOSPITAL CLÍNIC DE BARCELONA ( Site 0112), Barcelona

06800

RECRUITING

Ankara Bilkent Şehir Hastanesi. ( Site 0131), Çankaya

06620

RECRUITING

Ankara University Health Practice and Research Hospitals ( Site 0134), Ankara

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY